Clinical Immunotherapy Program Archives

Inspired by the potential of immunotherapy in solid tumor cancers, Tom and Nancy Chewning established a fund to support Jonathan Serody, MD, and accelerate his work with CAR-T immunotherapy.

As part of a study led by Matthew Foster, MD, the advance was seen in a patient enrolled in a clinical trial using CAR-T to treat refractory acute B-cell leukemia.

The European Medicines Agency granted priority medicines designation to Tessa Therapeutics’ CD30 targeted CAR-T therapy for patients with relapsed or refractory Hodgkin lymphoma.

Tag: Clinical Immunotherapy Program

Parents, supporters create new fund for CAR-T therapy

Precision Oncology News: Carisma Therapeutics Begins Study of CAR Macrophage Therapy for HER2-Overexpressing Solid Tumors

Engineered safety switch curbs severe side effects of CAR-T immunotherapy

European Medicines Agency awards priority designation for Hodgkin lymphoma CAR-T therapy

Pharmacy Times: Study Suggests Way to Boost Immunotherapy Against Breast Cancer, Other Solid Tumors

Fierce Biotech: Research Putting the ‘STING’ on CAR-T cells to turn them against breast cancer and other solid tumors

Drug Target Review: Activating STING enhances CAR T-cell activity in solid tumours, shows study

United Press International: Study: Modified immunotherapy may work in advanced breast cancer

Immuno-Oncology News: Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma Trial

Targeted Oncology: Autologous CAR T-Cell Therapy Induces Durable Responses in Relapsed/Refractory Hodgkin Lymphoma